Skip to content
RecruitingPhase 1

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

NCT06899334 · LPD · University Hospital, Basel, Switzerland

Recruiting
Status
Accepting participants
Phase 1
Phase
24
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The primary objective of this study is to determine whether equivalent moderately high doses of LSD, psilocybin, and DMT produce qualitatively similar peak effects when the effect duration is standardized with ketanserin. A DMT infusion mimicking oral LSD and psilocybin administrations will be tested, as well as intravenously administered ketanserin.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • 1. Altered state of consciousness profile (5D-ASC)

    Measured over 18 months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

25 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: 1. Good understanding of the German language 2. Understanding of procedures and risks associated with the study 3. Willing to adhere to the protocol and signing of the consent form 4. Willing to refrain from the consumption of illicit psychoactive substances during the study 5. Willing not to operate heavy machinery within 48 h after administration of a study substance 6. Willing to use effective birth control throughout study participation 7. Body mass index 17 - 34.9 kg/m2 Exclusion Criteria: 1. Relevant chronic or acute medical condition 2. Current or previous major psychiatric disorder (e.g. psychotic disorder) 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Bradycardia (\< 45 bpm) 6. Prolonged QTc interval (males: \>450 ms, females: \>470 ms) 7. AV block II° (Mobitz type and Webckebach type) and III° 8. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months 9. Pregnancy or current breastfeeding 10. Participation in another clinical trial (currently or within the last 30 days) 11. Use of medication that may interfere with the effects of the study medication 12. Tobacco smoking (\>10 cigarettes/day) 13. Excessive consumption of alcoholic beverages (\>15 drinks/week)

Where

1 study site

FacilityCityRegionCountry
University HospitalBaselSwitzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06899334 on ClinicalTrials.gov →

Last updated in the registry 2025-03-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits